Arcutis Biotherapeutics financials
$26.75−2.12%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $376.1M | $196.5M | $59.6M | $3.7M | $0.00 | $0.00 |
| Gross profit | $339.4M | $177.4M | $54.6M | $2.9M | $0.00 | $0.00 |
| Gross margin | 90.2% | 90.3% | 91.6% | 79.5% | — | — |
| Operating income | -$12.2M | -$128.4M | -$241.1M | -$301.6M | -$206.5M | -$136.6M |
| Net income | -$16.1M | -$140.0M | -$262.1M | -$311.5M | -$206.4M | -$135.7M |
| Net margin | −4.3% | −71.3% | −439.8% | −8449.8% | — | — |
| Diluted EPS | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 |
| EBITDA | -$12.2M | -$128.4M | -$241.1M | -$300.7M | -$205.8M | -$136.5M |
| Operating cash flow | -$5.6M | -$112.2M | -$247.1M | -$257.7M | -$174.6M | -$113.0M |
| Free cash flow | -$6.3M | -$112.3M | -$247.5M | -$258.0M | -$175.6M | -$113.4M |
| Diluted shares | 127.2M | 121.0M | 69.3M | 55.0M | 49.4M | 35.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $42.9M | $71.3M | $88.4M | $53.6M | $96.4M | $65.1M |
| Short-term investments | $178.1M | $156.6M | $183.5M | $355.9M | $290.6M | $219.4M |
| Total debt | $109.0M | $107.2M | $201.8M | $197.8M | $72.3M | $0.00 |
| Total assets | $433.0M | $348.9M | $341.4M | $449.3M | $408.2M | $298.3M |
| Total liabilities | $243.5M | $191.3M | $252.7M | $239.7M | $110.5M | $27.6M |
| Shareholders' equity | $189.5M | $157.5M | $88.7M | $209.6M | $297.7M | $270.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology